NCT05795400View on ClinicalTrials.gov

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

NAActive, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

February 26, 2025

Study Completion Date

June 30, 2025

Conditions
Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection FractionAmyloid Cardiomyopathy
Interventions
DRUG

Dapagliflozin 10mg Tab

10 mg tablets given once daily, per oral use

DRUG

Placebo

tablet of placebo drug dosed once daily

Trial Locations (1)

121552

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation, Moscow

All Listed Sponsors
lead

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

OTHER_GOV